Development of the clinical candidate PBD-C06, a humanized pGlu3-Aβ-specific antibody against Alzheimer’s disease with reduced complement activation

Effector function of anti-pyroglutamate-3 Aβ antibodies affects cognitive benefit, glial activation and amyloid clearance in Alzheimer’s-like mice

(2020) Helen Crehan et al.   Alzheimers Research & Therapy

2018 Alzheimer's disease facts and figures

(2018)   Alzheimers & Dementia

Anti-Amyloid-β Monoclonal Antibodies for Alzheimer’s Disease: Pitfalls and Promise

(2018) Christopher H. van Dyck   BIOLOGICAL PSYCHIATRY

The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade

(2018) Erika N. Cline et al.   JOURNAL OF ALZHEIMERS DISEASE

Passive Aβ Immunotherapy: Current Achievements and Future Perspectives

(2018) Stephan Schilling et al.   MOLECULES

Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer’s Disease

(2018) Michael F. Egan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease

(2018) Lawrence S. Honig et al.   NEW ENGLAND JOURNAL OF MEDICINE

Modified amyloid variants in pathological subgroups of β -amyloidosis

(2018) Janina Gerth et al.   Annals of Clinical and Translational Neurology

Glutaminyl Cyclase in Human Cortex: Correlation with (pGlu)-Amyloid-β Load and Cognitive Decline in Alzheimer's Disease

(2018) Markus Morawski et al.   JOURNAL OF ALZHEIMERS DISEASE

Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer’s disease: results of a randomized, double-blind, placebo-controlled phase 2a study

(2018) Philip Scheltens et al.   Alzheimers Research & Therapy

Structural and functional analyses of pyroglutamate-amyloid-β-specific antibodies as a basis for Alzheimer immunotherapy

(2017) Anke Piechotta et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Glutaminyl Cyclase Inhibitor PQ912 Improves Cognition in Mouse Models of Alzheimer’s Disease—Studies on Relation to Effective Target Occupancy

(2017) Torsten Hoffmann et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Semagacestat Is a Pseudo-Inhibitor of γ-Secretase

(2017) Shinji Tagami et al.   Cell Reports

The amyloid hypothesis of Alzheimer's disease at 25 years

(2016) Dennis J Selkoe et al.   EMBO Molecular Medicine

Aβ-Immunotherapeutic strategies: a wide range of approaches for Alzheimer's disease treatment

(2016) Laia Montoliu-Gaya et al.   EXPERT REVIEWS IN MOLECULAR MEDICINE

Immunotherapy targeting pyroglutamate-3 Aβ: prospects and challenges

(2016) Holger Cynis et al.   Molecular Neurodegeneration

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

(2016) Jeff Sevigny et al.   NATURE

Amyloid-β peptide protects against microbial infection in mouse and worm models of Alzheimer’s disease

(2016) Deepak Kumar Vijaya Kumar et al.   Science Translational Medicine

Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials

(2016) Rik Vandenberghe et al.   Alzheimers Research & Therapy

An anti-pyroglutamate-3 Aβ vaccine reduces plaques and improves cognition in APPswe/PS1ΔE9 mice

(2015) Jeffrey L. Frost et al.   NEUROBIOLOGY OF AGING

Impact of amyloid β aggregate maturation on antibody treatment in APP23 mice

(2015) Karthikeyan Balakrishnan et al.   Acta Neuropathologica Communications

Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimer’s disease

(2014) Thomas A. Bayer et al.   ACTA NEUROPATHOLOGICA

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CRENEZUMAB IN PATIENTS WITH MILD TO MODERATE ALZHEIMER'S DISEASE

(2014) Jeffrey Cummings et al.   Alzheimers & Dementia

Biochemical stages of amyloid-β peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically preclinical Alzheimer’s disease

(2014) Ajeet Rijal Upadhaya et al.   BRAIN

Phase I Trial of a Novel Anti-GD2 Monoclonal Antibody, Hu14.18K322A, Designed to Decrease Toxicity in Children With Refractory or Recurrent Neuroblastoma

(2014) Fariba Navid et al.   JOURNAL OF CLINICAL ONCOLOGY

Pyroglutamate-3 Amyloid-β Deposition in the Brains of Humans, Non-Human Primates, Canines, and Alzheimer Disease–Like Transgenic Mouse Models

(2013) Jeffrey L. Frost et al.   AMERICAN JOURNAL OF PATHOLOGY

Safety and Pharmacology of a Single Intravenous Dose of Ponezumab in Subjects With Mild-to-Moderate Alzheimer Disease

(2013) Jaren W. Landen et al.   CLINICAL NEUROPHARMACOLOGY

Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study

(2013) Victor L Villemagne et al.   LANCET NEUROLOGY

Pyroglutamate-Modified Amyloid-� Protein Demonstrates Similar Properties in an Alzheimer's Disease Familial Mutant Knock-In Mouse and Alzheimer's Disease Brain

(2013) Guoxin Wu et al.   Neurodegenerative Diseases

N-Terminal pyroglutamate formation of Aβ38 and Aβ40 enforces oligomer formation and potency to disrupt hippocampal long-term potentiation

(2012) Dagmar Schlenzig et al.   JOURNAL OF NEUROCHEMISTRY

Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β

(2012) Justin M. Nussbaum et al.   NATURE

Passive Immunization against Pyroglutamate-3 Amyloid-ß Reduces Plaque Burden in Alzheimer-Like Transgenic Mice: A Pilot Study

(2012) Jeffrey L. Frost et al.   Neurodegenerative Diseases

A Plaque-Specific Antibody Clears Existing β-amyloid Plaques in Alzheimer's Disease Mice

(2012) Ronald B. DeMattos et al.   NEURON

Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup

(2011) Reisa A. Sperling et al.   Alzheimers & Dementia

Pyroglutamate Amyloid-β (Aβ): A Hatchet Man in Alzheimer Disease

(2011) Sadim Jawhar et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

T-cell epitope mapping

(2010) Laurent Malherbe   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

Endogenous amyloid-β is necessary for hippocampal synaptic plasticity and memory

(2010) Daniela Puzzo et al.   ANNALS OF NEUROLOGY

Identification of Low Molecular Weight Pyroglutamate Aβ Oligomers in Alzheimer Disease

(2010) Oliver Wirths et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples

(2010) Margaret E. Ackerman et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Alzheimer's Disease

(2010) Henry W. Querfurth et al.   NEW ENGLAND JOURNAL OF MEDICINE

Intraneuronal pyroglutamate-Abeta 3–42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model

(2009) Oliver Wirths et al.   ACTA NEUROPATHOLOGICA

Pyroglutamate Formation Influences Solubility and Amyloidogenicity of Amyloid Peptides

(2009) Dagmar Schlenzig et al.   BIOCHEMISTRY

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

(2009) Clifford R Jack et al.   LANCET NEUROLOGY

RosettaAntibody: antibody variable region homology modeling server

(2009) A. Sircar et al.   NUCLEIC ACIDS RESEARCH

Glutaminyl cyclase inhibition attenuates pyroglutamate Aβ and Alzheimer's disease–like pathology

(2008) Stephan Schilling et al.   NATURE MEDICINE